Esperion Therapeutics, Inc. (ESPR): Price and Financial Metrics

Esperion Therapeutics, Inc. (ESPR)

Today's Latest Price: $30.79 USD

0.61 (-1.94%)

Updated Oct 28 11:07am

Add ESPR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ESPR Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ESPR is 2.53 -- better than 78.18% of US stocks.
  • ESPR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 86.73% of US stocks.
  • As for revenue growth, note that ESPR's revenue has grown 47.57% over the past 12 months; that beats the revenue growth of 89.56% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Esperion Therapeutics Inc, a group of peers worth examining would be NPTN, ALRM, EXEL, SMCI, and NVMI.
  • Visit ESPR's SEC page to see the company's official filings. To visit the company's web site, go to

ESPR Stock Price Chart Interactive Chart >

Price chart for ESPR

ESPR Price/Volume Stats

Current price $30.79 52-week high $76.98
Prev. close $31.40 52-week low $24.82
Day low $30.10 Volume 162,482
Day high $31.14 Avg. volume 696,968
50-day MA $35.03 Dividend yield N/A
200-day MA $42.86 Market Cap 856.73M

Esperion Therapeutics, Inc. (ESPR) Company Bio

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company was founded in 1998 and is based in Ann Arbor, Michigan.

ESPR Latest News Stream

Event/Time News Detail
Loading, please wait...

ESPR Latest Social Stream

Loading social stream, please wait...

View Full ESPR Social Stream

Latest ESPR News From Around the Web

Below are the latest news stories about Esperion Therapeutics Inc that investors may wish to consider to help them evaluate ESPR as an investment opportunity.

A drug developer with a franchise pointing to 372% upside - Needham

A quarterly report containing some below consensus sales for a new combination treatment from lipid-management company Esperion Therapeutics (ESPR) has ended up in at least one downgrade (to Neutral, from Credit Suisse) - but data pointing to a July prescription recovery points toward strong growth accelerating through the second half,...

Seeking Alpha | August 11, 2020

Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Ben Church - Corporate Communications Tim Mayleben - President & Chief Executive Officer Mark Glickman - Chief Commercial Officer Rick Bartram - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Geoff...

SA Transcripts on Seeking Alpha | August 11, 2020

Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets

ANN ARBOR, Mich., July 01, 2020 -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily.

Yahoo | July 1, 2020

Esperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting Bullish

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 23, 2020

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

Esperion (ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). Earlier this month, Esperion completed the transfer to DSE of Marketing Authorization Approvals (MAA) for NILEMDO and NUSTENDI.

Yahoo | June 22, 2020

Read More 'ESPR' Stories Here

ESPR Price Returns

1-mo -17.05%
3-mo -22.60%
6-mo -17.78%
1-year -25.95%
3-year -34.86%
5-year 28.29%
YTD -48.36%
2019 29.63%
2018 -30.13%
2017 425.88%
2016 -43.76%
2015 -44.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7985 seconds.